Some MEKi, included the one used in our study, have been approved by the US Food and Drug Administration for clinical applications as a monotherapy and/or as a combination therapy with the B-Raf inhibitors in BRAF-mutated melanoma, non-small cell lung carcinoma and neurofibromatosis [56–61]. The gene discussed is BRAF; the disease is neurofibromatosis.